Propanc Biopharma plans to acquire digital asset treasury companies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
November 4, 2025 7:00 AM ESTMELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (Propanc or the Company), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced a strategic initiative to pursue the acquisition of Digital Asset Treasury (DAT) companies that are currently trading below their Market Cap to Net Asset Value (MNAV).
The Companys management believes that acquiring undervalued DAT entities presents a compelling opportunity to strengthen Propancs balance sheet, diversify its asset base, and create long-term shareholder value. These DAT companies typically hold substantial reserves... More
